Self-inactivating, all-in-one AAV vectors for precision Cas9 genome editing via homology-directed repair in vivo
© 2021. The Author(s)..
Adeno-associated virus (AAV) vectors are important delivery platforms for therapeutic genome editing but are severely constrained by cargo limits. Simultaneous delivery of multiple vectors can limit dose and efficacy and increase safety risks. Here, we describe single-vector, ~4.8-kb AAV platforms that express Nme2Cas9 and either two sgRNAs for segmental deletions, or a single sgRNA with a homology-directed repair (HDR) template. We also use anti-CRISPR proteins to enable production of vectors that self-inactivate via Nme2Cas9 cleavage. We further introduce a nanopore-based sequencing platform that is designed to profile rAAV genomes and serves as a quality control measure for vector homogeneity. We demonstrate that these platforms can effectively treat two disease models [type I hereditary tyrosinemia (HT-I) and mucopolysaccharidosis type I (MPS-I)] in mice by HDR-based correction of the disease allele. These results will enable the engineering of single-vector AAVs that can achieve diverse therapeutic genome editing outcomes.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:12 |
|---|---|
| Enthalten in: |
Nature communications - 12(2021), 1 vom: 01. Nov., Seite 6267 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Ibraheim, Raed [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
CRISPR-Associated Protein 9 |
|---|
| Anmerkungen: |
Date Completed 24.12.2021 Date Revised 16.07.2022 published: Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1038/s41467-021-26518-y |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM332635694 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM332635694 | ||
| 003 | DE-627 | ||
| 005 | 20231225215955.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1038/s41467-021-26518-y |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1108.xml |
| 035 | |a (DE-627)NLM332635694 | ||
| 035 | |a (NLM)34725353 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Ibraheim, Raed |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Self-inactivating, all-in-one AAV vectors for precision Cas9 genome editing via homology-directed repair in vivo |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 24.12.2021 | ||
| 500 | |a Date Revised 16.07.2022 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2021. The Author(s). | ||
| 520 | |a Adeno-associated virus (AAV) vectors are important delivery platforms for therapeutic genome editing but are severely constrained by cargo limits. Simultaneous delivery of multiple vectors can limit dose and efficacy and increase safety risks. Here, we describe single-vector, ~4.8-kb AAV platforms that express Nme2Cas9 and either two sgRNAs for segmental deletions, or a single sgRNA with a homology-directed repair (HDR) template. We also use anti-CRISPR proteins to enable production of vectors that self-inactivate via Nme2Cas9 cleavage. We further introduce a nanopore-based sequencing platform that is designed to profile rAAV genomes and serves as a quality control measure for vector homogeneity. We demonstrate that these platforms can effectively treat two disease models [type I hereditary tyrosinemia (HT-I) and mucopolysaccharidosis type I (MPS-I)] in mice by HDR-based correction of the disease allele. These results will enable the engineering of single-vector AAVs that can achieve diverse therapeutic genome editing outcomes | ||
| 650 | 4 | |a Evaluation Study | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, N.I.H., Extramural | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 7 | |a CRISPR-Associated Protein 9 |2 NLM | |
| 650 | 7 | |a EC 3.1.- |2 NLM | |
| 700 | 1 | |a Tai, Phillip W L |e verfasserin |4 aut | |
| 700 | 1 | |a Mir, Aamir |e verfasserin |4 aut | |
| 700 | 1 | |a Javeed, Nida |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Jiaming |e verfasserin |4 aut | |
| 700 | 1 | |a Rodríguez, Tomás C |e verfasserin |4 aut | |
| 700 | 1 | |a Namkung, Suk |e verfasserin |4 aut | |
| 700 | 1 | |a Nelson, Samantha |e verfasserin |4 aut | |
| 700 | 1 | |a Khokhar, Eraj Shafiq |e verfasserin |4 aut | |
| 700 | 1 | |a Mintzer, Esther |e verfasserin |4 aut | |
| 700 | 1 | |a Maitland, Stacy |e verfasserin |4 aut | |
| 700 | 1 | |a Chen, Zexiang |e verfasserin |4 aut | |
| 700 | 1 | |a Cao, Yueying |e verfasserin |4 aut | |
| 700 | 1 | |a Tsagkaraki, Emmanouela |e verfasserin |4 aut | |
| 700 | 1 | |a Wolfe, Scot A |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Dan |e verfasserin |4 aut | |
| 700 | 1 | |a Pai, Athma A |e verfasserin |4 aut | |
| 700 | 1 | |a Xue, Wen |e verfasserin |4 aut | |
| 700 | 1 | |a Gao, Guangping |e verfasserin |4 aut | |
| 700 | 1 | |a Sontheimer, Erik J |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Nature communications |d 2010 |g 12(2021), 1 vom: 01. Nov., Seite 6267 |w (DE-627)NLM199274525 |x 2041-1723 |7 nnns |
| 773 | 1 | 8 | |g volume:12 |g year:2021 |g number:1 |g day:01 |g month:11 |g pages:6267 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1038/s41467-021-26518-y |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 12 |j 2021 |e 1 |b 01 |c 11 |h 6267 | ||